This podcast discusses the article "Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study." The multinational study explores real world evidence on the use of sodium-glucose cotransporter-2. As the incidence of type 2 diabetes mellitus rises in the United States, understanding the cardioprotective effects of new drug classes will prepare you to better treat your patients.

Subscribe on iTunes | Subscribe on Google Play | View in the Educational Activity

Keywords: CardiaCast, Diabetes Mellitus, Cardiotonic Agents, Metabolic Syndrome

< Back to Listings